MLN2704

DB06513InvestigationalProtein Based Therapies

A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.

Mechanism: Pharmacologically active on Glutamate carboxypeptidase 2
Curator reviewed
Primary indication: Investigated for use/treatment in prostate cancer.Curator reviewed
Code names: MLN2704 · MLN591

Resolves to

Targets

Q04609FOLH1

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with MLN2704, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account